Christine Tkaczyk

Christine Tkaczyk is Director in the Microbial Antibody Technology group within Early Vaccines & immune Therapies at AstraZeneca, Gaithersburg, USA. At AstraZeneca, she spent 18 years developing monoclonal antibodies for serious bacterial infections. More recently, she expanded her research to develop mRNA platform for delivering diverse formats of monoclonal antibodies in vivo.